<?xml version="1.0" encoding="UTF-8"?>
<ref id="B35-vaccines-07-00074">
 <label>35.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sather</surname>
    <given-names>D.N.</given-names>
   </name>
   <name>
    <surname>Carbonetti</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Kehayia</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Kraft</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Mikell</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Scheid</surname>
    <given-names>J.F.</given-names>
   </name>
   <name>
    <surname>Klein</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Stamatatos</surname>
    <given-names>L.</given-names>
   </name>
  </person-group>
  <article-title>Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus</article-title>
  <source>J. Virol.</source>
  <year>2012</year>
  <volume>86</volume>
  <fpage>12676</fpage>
  <lpage>12685</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.01893-12</pub-id>
  <pub-id pub-id-type="pmid">22973035</pub-id>
 </element-citation>
</ref>
